DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients?

Author(s): Hoppe C, Rademacher M, Hoffmann JM, Schmidt D, Elger CE

Affiliation(s): Department of Epileptology, University of Bonn Medical Centre, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany. christian.hoppe@ukb.uni-bonn.de

Publication date & source: 2008-06, Seizure., 17(4):327-32. Epub 2007 Dec 3.

Publication type: Randomized Controlled Trial

OBJECTIVE: To evaluate bodyweight gain during pregabalin therapy for epilepsy and the utility of a short counseling program to prevent this side effect. METHODS: Randomized controlled trial on the effects of extended versus standard patient counseling on the risk of bodyweight gain with 3- and 6-month follow-up including a consecutive sample of adult outpatients with epilepsy eligible for pregabalin add-on treatment (N=98). RESULTS: The seizure response rate was about 30%, the seizure freedom rate was 5% at the 6-month follow-up (intent-to-treat sample, N=98). The median bodyweight gain for the according-to-protocol sample (N=62) was 4.0 kg with no effect of extended counseling. Bodyweight gain was correlated with number of anticonvulsant drugs (r=.32, p<.05). CONCLUSIONS: Pregabalin treatment is associated with a high risk for bodyweight gain which in part depends on total anticonvulsant drug load. This side effect cannot be prevented by extended patient counseling within a standard clinical setting.

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017